Implementation of New Basic Medical Insurance Drug List and Initial Commercial Insurance Innovative Drug List in Mainland China Next Year

Written by Emily J. Thompson, Senior Investment Analyst

Source: aastocks

Updated: Nov 04 2025

0mins

Should l Buy ?

Source: aastocks

Negotiations for Drug Lists: China's National Healthcare Security Administration (NHSA) held negotiations for the 2025 National Basic Medical Insurance Drug List and the Commercial Insurance Innovative Drug List, with participation from 120 domestic and foreign enterprises.
Outcome of Negotiations: The negotiations concluded successfully, involving 127 drugs not currently on the National Basic Medical Insurance Drug List and 24 drugs for the Commercial Insurance Innovative Drug List.
Release Plans: The new drug lists are set to be released both online and offline in Guangzhou on the first weekend of next month.
Implementation Timeline: The new lists will officially take effect starting next year after completing necessary technical, administrative, and legal procedures.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

GET FREE REAL TIME NOTIFICATIONS

Stock Monitor for NVDA?

Get Started Free

FREE STOCK RECOMMENDATIONS DAILY

Stock Bullish Tomorrow

Get Started Free

70% BACKTESTED ACCURACY!

Should I Buy NVDA?

Get Started Free